Radioembolization and Ipilimumab in Treating Patients With Uveal Melanoma With Liver Metastases

PRIMARY OBJECTIVE: I. To estimate the safety and efficacy of sequential hepatic radioembolization and systemic ipilimumab in patients with uveal melanoma metastatic to liver. SECONDARY OBJECTIVES: I. To evaluate effects on regulators of tumor immunity. OUTLINE: Patients undergo radioembolization with yttrium Y 90 glass microspheres via hepatic arterial infusion on day 1. Beginning on day 29, patients also receive ipilimumab intravenously (IV) over 90 minutes. Treatment with ipilimumab repeats every 3 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up for 5 years.